Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma

Ni Fan; Lu Zhang; Xiaoping Xu; Bobin Chen; Chen Zhu; Pei Li; Zi Chen; Tianling Ding; Yan Ma; Yan Yuan; Zhiguang Lin

doi:10.18632/oncotarget.15899

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Learn about our FREE

Post-Publication Promotion Services

50% on all publication fees until the end of 2024.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Clinical Research Papers:

Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma

Ni Fan, Lu Zhang, Xiaoping Xu _, Bobin Chen, Chen Zhu, Pei Li, Zi Chen, Tianling Ding, Yan Ma, Yan Yuan and Zhiguang Lin

PDF | HTML | How to cite

Oncotarget. 2017; 8:53701-53713. https://doi.org/10.18632/oncotarget.15899

Metrics: PDF 1758 views | HTML 2297 views | ?

Abstract

Ni Fan1,*, Lu Zhang1,*, Xiaoping Xu1, Bobin Chen1, Chen Zhu1, Pei Li1, Zi Chen1, Tianling Ding1, Yan Ma1, Yan Yuan1 and Zhiguang Lin1

1 Department of Hematology, Huashan Hospital, Fudan University, Shanghai, China

Correspondence to:

Xiaoping Xu, email:

Bobin Chen, email:

Keywords: PCNSL, methotrexate, idarubicin, PFS

Received: September 06, 2016 Accepted: February 07, 2017 Published: March 04, 2017

Abstract

Primary central nervous system lymphoma (PCNSL) is a rare form of non-Hodgkin lymphoma with poor long-term survival. This study assessed methotrexate (MTX) plus idarubicin (IDA) in treating patients of PCNSL comparing to MTX alone therapy. A total of 100 patients were retrospectively enrolled and subjected to MTX alone (n = 52) and MTX plus IDA (n = 48). The completed response (CR) rate in patients treated with MTX plus IDA was 62.50%, and overall response (OR) rate was 79.17%, which in MTX alone cohort were 42.31% and 63.46% respectively. Median progression-free survival (PFS) of patients treated with MTX plus IDA was significantly better than those treated with MTX alone (18.35 months vs.8.45months, P = 0.000). The MTX plus IDA regimen exhibited a significantly better control of PCNSL. Further studies would be needed to confirm these results.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 15899

Publication Alerts

Post-Publication Promotion

Publication Discount

Clinical Research Papers:

Methotrexate plus idarubicin improves outcome of patients with primary central nervous system lymphoma

Abstract